Literature DB >> 16480796

Do recommended high-risk adults benefit from a first influenza vaccination?

E Hak1, E Buskens, K L Nichol, T J M Verheij.   

Abstract

It is unknown whether a first influenza vaccination protects high-risk adults from severe morbidity and mortality during influenza epidemics. As part of the PRISMA nested case-control study, we aimed to evaluate the effectiveness of first-time and repeat influenza vaccinations in adult persons recommended for vaccination aged between 18 and 64 years during the 1999-2000 influenza A epidemic. After adjustments, 69% of hospitalizations for acute respiratory or cardiovascular disease or death were prevented in first-time vaccinees (95% percent confidence interval [95% CI]: 8-90%). The corresponding figure in persons who were vaccinated before was 85% (95% CI: 36-96%). Adult persons with high-risk medical conditions can substantially benefit from a first and repeat influenza vaccination prior to an epidemic.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480796     DOI: 10.1016/j.vaccine.2006.01.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Prognosis of primary care patients aged 80 years and older with lower respiratory tract infection.

Authors:  Christiana van de Nadort; Hugo M Smeets; Jettie Bont; N Peter A Zuithoff; Eelko Hak; Theo J M Verheij
Journal:  Br J Gen Pract       Date:  2009-04       Impact factor: 5.386

2.  Seasonal Influenza Vaccine Effectiveness in the community (SIVE): protocol for a cohort study exploiting a unique national linked data set.

Authors:  Nazir I Lone; Colin Simpson; Kimberley Kavanagh; Chris Robertson; Jim McMenamin; Lewis Ritchie; Aziz Sheikh
Journal:  BMJ Open       Date:  2012-03-15       Impact factor: 2.692

3.  A comparison of populations vaccinated in a public service and in a private hospital setting in the same area.

Authors:  Elisabetta Pandolfi; Maria C Graziani; Roberto Ieraci; Giovanni Cavagni; Alberto E Tozzi
Journal:  BMC Public Health       Date:  2008-08-06       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.